
Clovis Oncology (CLVS) rose in trading today due to positive news on one of its products. The company’s Rubraca product received a positive opinion from CHMP as a maintenance treatment for women with relapsed ovarian cancer. CLVS shares were up over +4% as of the time this content was created. Here is a recap of what happened.